Rasonque 几乎把胰腺癌患者的平均存活期延长一倍。什么是疗效显著？这才 TMD 叫疗效显著！
有些所谓的新药、新疫苗靠统计学搞出个百分之十几、百分之二十几所谓的“显著”差异，糊弄傻子呢。
FDA approves new pancreatic cancer drug expected to usher in new era of treatment
https://www.statnews.com/2026/08/26/pan ... -approved/
By Adam Feuerstein and Angus Chen
The therapy, Rasonque from Revolution Medicines, nearly doubled overall survival in a clinical trial.
The Food and Drug Administration on Wednesday approved a life-extending treatment for advanced pancreatic cancer — a medicine made by the biotech company Revolution Medicines that is the first to attack a genetic cause of the aggressive, highly lethal malignancy.
The drug, called daraxonrasib, will be sold under the brand name Rasonque. The FDA’s approval was supported by a practice-changing clinical trial that read out earlier this year. Patients with advanced pancreatic cancer who received Rasonque as a second-line treatment achieved a median overall survival of 13.2 months, compared to 6.7 months for patients offered standard chemotherapy.
FDA 批准该药的消息出来后，生产该药的公司 Revolution Medicines (RVMD) 股价没有明显波动，可能前一段时间已经涨过了、priced-in。
(1)